Welcome to LookChem.com Sign In|Join Free
  • or
MEPHENESIN is a centrally acting skeletal muscle relaxant that belongs to the class of drugs known as benzodiazepines. It works by depressing the central nervous system, specifically the polysynaptic pathways of the spinal cord, to produce muscle relaxation. This makes it useful in treating muscle spasms and pain associated with various conditions.

59-47-2

Post Buying Request

59-47-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

59-47-2 Usage

Uses

Used in Pharmaceutical Industry:
MEPHENESIN is used as a muscle relaxant for the treatment of muscle spasms and pain resulting from various conditions, such as sprains, strains, and back pain. Its ability to depress the central nervous system and reduce muscle spasms makes it an effective treatment option.
Used in Research and Development:
MEPHENESIN has been utilized in the study of ligand-based virtual screening and design of antimalarial compounds. This application highlights its potential in contributing to the development of new drugs for various medical conditions.
Brand names associated with MEPHENESIN include Tolserol (Bristol-Myers Squibb), Bioglan m/q, Decontracyl-baum, Geno-sal, Glykresinum, Glyptol, Kencaps, Mefentil, Mepha-gesic, Mephesol, Midisalb-m, Myocalm, Myolisysin, Neo-xoline-m, Nochyrol, Relaxil-g, Rhex "hobein", Salimed compound, and Walconesin. These brand names indicate the widespread use and availability of MEPHENESIN in the pharmaceutical market for various applications.

Originator

Tolserol,Squibb,US,1948

Manufacturing Process

Into an iron or copper reaction vessel having an efficient stirring device and furnished with a refluxing column and condenser, were charged 330 lb of high quality meta-cresol and 150 lb of glycerol, together with 25 lb of sodium acetate to serve as the catalyst in the reaction. The reaction mixture, of this composition, was then heated to 250°C. The water of the reaction distilled off during the heating as the ether formation proceeded, this removal of water from the reaction chamber being promoted by the presence of the excess of phenol, some of which also continued to distill over. Towards the end of the reaction, after about 12 hours, when about 60% of the glycerol had been converted, at which point the reaction slowed down and the distillate was mainly cresol, the batch was cooled and 50 gallons of water were added to it along with 150 lb of xylene. As the result of these additions and the cooling down of the material the batch stratified into an aqueous layer containing unreacted glycerol, polyglycerols and sodium acetate, and a nonaqueous layer containing the ethers that had been formed in the reaction, together with unreacted cresol which remained in the reaction chamber, dissolved in the xylene that had been added to the batch. The aqueous layer was then separated and the water content removed therefrom by evaporation to a degree suitable for the recovery of the glycerol and sodium acetate contents of the layer, for their reuse in the process in a succeeding batch therein. The separated nonaqueous layer containing the ethers was distilled to recover the xylene and cresol contents respectively as the early fractions of the layer thus subjected to distillation. The cresol thus recovered, together with the cresol recovered from the distillate obtained during the heating of the reaction mixture, was returned to the process for reuse in a succeeding batch. Redistillation of the ether mixture recovered is usually necessary and desirable, particularly from the point of view of removing last traces of cresol therefrom. The yield of mixed ethers in this example was about 200 lb, in the relative proportions stated of about 70 parts of monoether to 30 of diether.

Therapeutic Function

Muscle relaxant

World Health Organization (WHO)

Mephenesin, a centrally acting muscle relaxant and sedative, was introduced in 1948 and its use has subsequently been associated with some of the undesirable features of barbiturate use. It is of limited efficacy since it is shortacting and does not relieve the spasticity associated with chronic neurological disorders. It has therefore been largely superseded by benzodiazepines but it remains available in some countries.

Check Digit Verification of cas no

The CAS Registry Mumber 59-47-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 9 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 59-47:
(4*5)+(3*9)+(2*4)+(1*7)=62
62 % 10 = 2
So 59-47-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H14O3/c1-8-4-2-3-5-10(8)13-7-9(12)6-11/h2-5,9,11-12H,6-7H2,1H3

59-47-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (B21928)  3-(2-Methylphenoxy)-1,2-propanediol, 98%   

  • 59-47-2

  • 25g

  • 250.0CNY

  • Detail
  • Alfa Aesar

  • (B21928)  3-(2-Methylphenoxy)-1,2-propanediol, 98%   

  • 59-47-2

  • 100g

  • 897.0CNY

  • Detail
  • Alfa Aesar

  • (B21928)  3-(2-Methylphenoxy)-1,2-propanediol, 98%   

  • 59-47-2

  • 500g

  • 3361.0CNY

  • Detail
  • Aldrich

  • (286567)  Mephenesin  98%

  • 59-47-2

  • 286567-500G

  • 3,340.35CNY

  • Detail

59-47-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-(2-methylphenoxy)propane-1,2-diol

1.2 Other means of identification

Product number -
Other names Lissenphan

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:59-47-2 SDS

59-47-2Synthetic route

ortho-cresol
95-48-7

ortho-cresol

3-monochloro-1,2-propanediol
96-24-2

3-monochloro-1,2-propanediol

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
With sodium hydroxide In N,N-dimethyl-formamide at 210℃; for 0.25h; Microwave irradiation;94%
With sodium hydroxide In ethanol for 2h; Heating;79%
With sodium hydroxide; water
With sodium ethanolate
With sodium ethanolate 1.) EtOH, RT, 30 min, 2.) EtOH, a) reflux, 4 h, b) RT, overnight; Yield given. Multistep reaction;
oxiranyl-methanol
556-52-5

oxiranyl-methanol

ortho-cresol
95-48-7

ortho-cresol

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
With tetrabutylammomium bromide; potassium carbonate; palladium dichloride In water at 60℃; for 5h;66%
With tetrabutylammomium bromide; sodium hydroxide at 20℃; for 5h;0.7 g
ortho-cresol
95-48-7

ortho-cresol

glycerol
56-81-5

glycerol

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
With carbon dioxide; calcium oxide at 200℃;
With sodium acetate at 200 - 210℃;
With potassium carbonate; Diethyl carbonate at 105 - 110℃; for 28h;76 %Spectr.
Etherification;
sodium hydroxide Etherification;
3-monochloro-1,2-propanediol
96-24-2

3-monochloro-1,2-propanediol

sodium o-cresolate
4549-72-8

sodium o-cresolate

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
With water
With ethanol
o-Cresyl glycidyl ether
2210-79-9

o-Cresyl glycidyl ether

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
With sulfuric acid for 1h; Ambient temperature;
With water at 25℃; pH=7.2; Microbiological reaction; Enzymatic reaction; enantioselective reaction;
Acetic acid 1-acetoxymethyl-2-o-tolyloxy-ethyl ester
63991-86-6

Acetic acid 1-acetoxymethyl-2-o-tolyloxy-ethyl ester

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
With sodium hydroxide In isopropyl alcohol at 85℃; Hydrolysis;20 mg
epichlorohydrin
106-89-8

epichlorohydrin

potassium-<2-methyl-phenolate>

potassium-<2-methyl-phenolate>

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
With water Erhitzen des Reaktionsprodukts mit wss. Na2CO3;
1-chloro-3-(2-methylphenoxy)propan-2-ol
25772-91-2

1-chloro-3-(2-methylphenoxy)propan-2-ol

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 231 mg / NaH / ethyl acetate; hexane / 0.08 h
2: 100 - 110 °C
3: 20 mg / aq. NaOH / propan-2-ol / 85 °C
View Scheme
o-Cresyl glycidyl ether
2210-79-9

o-Cresyl glycidyl ether

(+-)-1-methyl-heptylamine

(+-)-1-methyl-heptylamine

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 100 - 110 °C
2: 20 mg / aq. NaOH / propan-2-ol / 85 °C
View Scheme
ortho-cresol
95-48-7

ortho-cresol

C-chloro-formamidine hydrochloride

C-chloro-formamidine hydrochloride

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: aq. NaOH / propan-2-ol / 84 °C
2: 231 mg / NaH / ethyl acetate; hexane / 0.08 h
3: 100 - 110 °C
4: 20 mg / aq. NaOH / propan-2-ol / 85 °C
View Scheme
ortho-cresol
95-48-7

ortho-cresol

Fuller's earth

Fuller's earth

mephenesin
59-47-2

mephenesin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: K2CO3 / acetone / Heating
2: 1N sulfuric acid / 1 h / Ambient temperature
View Scheme
carbon dioxide
124-38-9

carbon dioxide

o-Cresyl glycidyl ether
2210-79-9

o-Cresyl glycidyl ether

A

mephenesin
59-47-2

mephenesin

B

4-[(2-methylphenoxy)methyl]-1,3-dioxolan-2-one
1878-24-6

4-[(2-methylphenoxy)methyl]-1,3-dioxolan-2-one

Conditions
ConditionsYield
With C44H22Cl8N4(2-)*Mn(3+)*IO3(1-); tetrabutylammomium bromide In neat (no solvent) under 750.075 Torr; for 120h; Catalytic behavior; Heating;
vinyl acetate
108-05-4

vinyl acetate

mephenesin
59-47-2

mephenesin

1-acetoxy-3-(2-methylphenoxy)propan-2-ol
138710-05-1, 105476-17-3

1-acetoxy-3-(2-methylphenoxy)propan-2-ol

Conditions
ConditionsYield
With porcine pancreatic lipase In di-isopropyl ether at 20℃; for 3h; Enzymatic reaction; regioselective reaction;97%
divinyl butanedioate
13416-90-5

divinyl butanedioate

mephenesin
59-47-2

mephenesin

1-O-vinylsuccinylmephenesin
929005-15-2

1-O-vinylsuccinylmephenesin

Conditions
ConditionsYield
With Lipozyme(R) In acetone at 50℃; for 1h;85.2%
divinyl adipate
4074-90-2

divinyl adipate

mephenesin
59-47-2

mephenesin

1-O-vinyladipoyl-mephenesin

1-O-vinyladipoyl-mephenesin

Conditions
ConditionsYield
With Lipozyme(R) In acetone at 50℃; for 2h;78.5%
mephenesin
59-47-2

mephenesin

acetic anhydride
108-24-7

acetic anhydride

1-acetoxy-3-(2-methylphenoxy)propan-2-ol
138710-05-1, 105476-17-3

1-acetoxy-3-(2-methylphenoxy)propan-2-ol

Conditions
ConditionsYield
With pyridine; dmap In dichloromethane66%
azelaic acid divinyl ester
10355-49-4

azelaic acid divinyl ester

mephenesin
59-47-2

mephenesin

1-O-vinylazeloyl-mephenesin

1-O-vinylazeloyl-mephenesin

Conditions
ConditionsYield
With Lipozyme(R) In acetone at 50℃; for 2h;64.1%
divinyl sebacate
10355-50-7

divinyl sebacate

mephenesin
59-47-2

mephenesin

1-O-vinylsebacoyl-mephenesin

1-O-vinylsebacoyl-mephenesin

Conditions
ConditionsYield
With Lipozyme(R) In acetone at 50℃; for 2h;60%
vinyl acetate
108-05-4

vinyl acetate

mephenesin
59-47-2

mephenesin

Acetic acid (S)-1-acetoxymethyl-2-o-tolyloxy-ethyl ester
138710-06-2

Acetic acid (S)-1-acetoxymethyl-2-o-tolyloxy-ethyl ester

Conditions
ConditionsYield
In tetrahydrofuran for 240h; Ambient temperature; lipase Amano PS;35%
1-(2,2-dimethoxyethyl)piperidine
22633-62-1

1-(2,2-dimethoxyethyl)piperidine

mephenesin
59-47-2

mephenesin

1-(4-o-tolyloximethyl-[1,3]dioxolan-2-ylmethyl)-piperidine
98654-32-1

1-(4-o-tolyloximethyl-[1,3]dioxolan-2-ylmethyl)-piperidine

Conditions
ConditionsYield
at 120℃;
succinic acid anhydride
108-30-5

succinic acid anhydride

mephenesin
59-47-2

mephenesin

succinic acid mono-(β-hydroxy-β'-o-tolyloxy-isopropyl ester)

succinic acid mono-(β-hydroxy-β'-o-tolyloxy-isopropyl ester)

Conditions
ConditionsYield
With pyridine Erhitzen auf dem Dampfbad;
Trimethyl orthoacetate
1445-45-0

Trimethyl orthoacetate

mephenesin
59-47-2

mephenesin

2-methoxy-2-methyl-4-o-tolyloximethyl-[1,3]dioxolane

2-methoxy-2-methyl-4-o-tolyloximethyl-[1,3]dioxolane

phosgene
75-44-5

phosgene

mephenesin
59-47-2

mephenesin

2-hydroxy-3-(o-tolyloxy)propyl carbamate
533-06-2

2-hydroxy-3-(o-tolyloxy)propyl carbamate

Conditions
ConditionsYield
With N,N-dimethyl-aniline; benzene Behandeln einer Loesung des Reaktionsprodukts in Benzol mit wss. NH3;
phosgene
75-44-5

phosgene

mephenesin
59-47-2

mephenesin

1,2-bis-carbamoyloxy-3-o-tolyloxy-propane
100254-95-3

1,2-bis-carbamoyloxy-3-o-tolyloxy-propane

Conditions
ConditionsYield
With antipyrine; chloroform; toluene Behandeln der vom Antipyrin-hydrochlorid befreiten Reaktionsloesung mit NH3;
phosgene
75-44-5

phosgene

mephenesin
59-47-2

mephenesin

4-[(2-methylphenoxy)methyl]-1,3-dioxolan-2-one
1878-24-6

4-[(2-methylphenoxy)methyl]-1,3-dioxolan-2-one

Conditions
ConditionsYield
With antipyrine; chloroform; toluene
n-pentyl methyl ketone
110-43-0

n-pentyl methyl ketone

mephenesin
59-47-2

mephenesin

2-methyl-2-pentyl-4-o-tolyloximethyl-[1,3]dioxolane
6288-82-0

2-methyl-2-pentyl-4-o-tolyloximethyl-[1,3]dioxolane

Conditions
ConditionsYield
With toluene-4-sulfonic acid; toluene
chloroacetaldehyde dimethyl acetal
97-97-2

chloroacetaldehyde dimethyl acetal

mephenesin
59-47-2

mephenesin

2-chloromethyl-4-o-tolyloximethyl-[1,3]dioxolane
100388-92-9

2-chloromethyl-4-o-tolyloximethyl-[1,3]dioxolane

Conditions
ConditionsYield
With sulfuric acid
trimethyl orthovalerate
13820-09-2

trimethyl orthovalerate

mephenesin
59-47-2

mephenesin

2-butyl-2-methoxy-4-o-tolyloximethyl-[1,3]dioxolane

2-butyl-2-methoxy-4-o-tolyloximethyl-[1,3]dioxolane

Conditions
ConditionsYield
With sulfuric acid
mephenesin
59-47-2

mephenesin

pyridine-3-carbonyl chloride hydrochloride
20260-53-1

pyridine-3-carbonyl chloride hydrochloride

nicotinic acid-(2-hydroxy-3-o-tolyloxy-propyl ester)
533-07-3

nicotinic acid-(2-hydroxy-3-o-tolyloxy-propyl ester)

Conditions
ConditionsYield
With pyridine
mephenesin
59-47-2

mephenesin

5-o-tolyloxymethyl-oxazolidin-2-one
1505-68-6

5-o-tolyloxymethyl-oxazolidin-2-one

phosgene
75-44-5

phosgene

mephenesin
59-47-2

mephenesin

ethylamine
75-04-7

ethylamine

ethyl-carbamic acid-(2-hydroxy-3-o-tolyloxy-propyl ester)
6288-77-3

ethyl-carbamic acid-(2-hydroxy-3-o-tolyloxy-propyl ester)

mephenesin
59-47-2

mephenesin

Triethyl orthoacetate
78-39-7

Triethyl orthoacetate

2-ethoxy-2-methyl-4-o-tolyloximethyl-[1,3]dioxolane

2-ethoxy-2-methyl-4-o-tolyloximethyl-[1,3]dioxolane

mephenesin
59-47-2

mephenesin

chloral
75-87-6

chloral

1-o-tolyloxy-2,3-bis-(2,2,2-trichloro-1-hydroxy-ethoxy)-propane
6055-48-7

1-o-tolyloxy-2,3-bis-(2,2,2-trichloro-1-hydroxy-ethoxy)-propane

Conditions
ConditionsYield
With toluene
phosgene
75-44-5

phosgene

mephenesin
59-47-2

mephenesin

ethylenediamine
107-15-3

ethylenediamine

(2-amino-ethyl)-carbamic acid-(2-hydroxy-3-o-tolyloxy-propyl ester)
106381-70-8

(2-amino-ethyl)-carbamic acid-(2-hydroxy-3-o-tolyloxy-propyl ester)

mephenesin
59-47-2

mephenesin

orthoformic acid triethyl ester
122-51-0

orthoformic acid triethyl ester

2-ethoxy-4-o-tolyloxymethyl-[1,3]dioxolane
131868-26-3

2-ethoxy-4-o-tolyloxymethyl-[1,3]dioxolane

mephenesin
59-47-2

mephenesin

Triethyl orthopropionate
115-80-0

Triethyl orthopropionate

2-ethoxy-2-ethyl-4-o-tolyloximethyl-[1,3]dioxolane

2-ethoxy-2-ethyl-4-o-tolyloximethyl-[1,3]dioxolane

Conditions
ConditionsYield
With sulfuric acid
mephenesin
59-47-2

mephenesin

Diethyl carbonate
105-58-8

Diethyl carbonate

4-[(2-methylphenoxy)methyl]-1,3-dioxolan-2-one
1878-24-6

4-[(2-methylphenoxy)methyl]-1,3-dioxolan-2-one

Conditions
ConditionsYield
With sodium methylate Entfernen des entstehenden Aethanols;
ethyl 2-hydroxyacetate
623-50-7

ethyl 2-hydroxyacetate

mephenesin
59-47-2

mephenesin

1-Glycoloyloxy-3-o-tolyloxypropan-2-ol
100258-09-1

1-Glycoloyloxy-3-o-tolyloxypropan-2-ol

Conditions
ConditionsYield
With toluene-4-sulfonic acid

59-47-2Relevant academic research and scientific papers

Ligand-Free Copper-Catalyzed Ullmann-Type C?O Bond Formation in Non-Innocent Deep Eutectic Solvents under Aerobic Conditions

Capriati, Vito,García-álvarez, Joaquín,Marinò, Manuela,Perna, Filippo M.,Quivelli, Andrea Francesca,Vitale, Paola

, (2021/12/09)

An efficient and novel protocol was developed for a Cu-catalyzed Ullmann-type aryl alkyl ether synthesis by reacting various (hetero)aryl halides (Cl, Br, I) with alcohols as active components of environmentally benign choline chloride-based eutectic mixtures. Under optimized conditions, the reaction proceeded under mild conditions (80 °C) in air, in the absence of additional ligands, with a catalyst [CuI or CuII species] loading up to 5 mol% and K2CO3 as the base, providing the desired aryloxy derivatives in up to 98 % yield. The potential application of the methodology was demonstrated in the valorization of cheap, easily available, and naturally occurring polyols (e. g., glycerol) for the synthesis of some pharmacologically active aryloxypropanediols (Guaiphenesin, Mephenesin, and Chlorphenesin) on a 2 g scale in 70–96 % yield. Catalyst, base, and deep eutectic solvent could easily and successfully be recycled up to seven times with an E-factor as low as 5.76.

Highly regio- and enantio-selective hydrolysis of two racemic epoxides by GmEH3, a novel epoxide hydrolase from Glycine max

Zhang, Chen,Li, Chuang,Zhu, Xiu-xiu,Liu, You-yi,Zhao, Jun,Wu, Min-chen

, p. 2795 - 2803 (2020/09/01)

A novel epoxide hydrolase from Glycine max, designated GmEH3, was excavated based on the computer-aided analysis. Then, gmeh3, a GmEH3-encoding gene, was cloned and successfully expressed in E. coli Rosetta(DE3). Among the ten investigated rac-epoxides, GmEH3 possessed the highest and best complementary regioselectivities (regioselectivity coefficients, αS = 93.7% and βR = 97.2%) in the asymmetric hydrolysis of rac-m-chlorostyrene oxide (5a), and the highest enantioselectivity (enantiomeric ratio, E = 55.6) towards rac-phenyl glycidyl ether (7a). The catalytic efficiency (kcatS/KmS = 2.50 mM?1 s?1) of purified GmEH3 for (S)-5a was slightly higher than that (kcatR/KmR = 1.52 mM?1 s?1) for (R)-5a, whereas the kcat/Km (5.16 mM?1 s?1) for (S)-7a was much higher than that (0.09 mM?1 s?1) for (R)-7a. Using 200 mg/mL wet cells of E. coli/gmeh3 as the biocatalyst, the scale-up enantioconvergent hydrolysis of 150 mM rac-5a at 25 °C for 1.5 h afforded (R)-5b with 90.2% eep and 95.4% yieldp, while the kinetic resolution of 500 mM rac-7a for 2.5 h retained (R)-7a with over 99% ees and 43.2% yields. Furthermore, the sources of high regiocomplementarity of GmEH3 for (S)- and (R)-5a as well as high enantioselectivity towards rac-7a were analyzed via molecular docking (MD) simulation.

MnIII Porphyrins: Catalytic Coupling of Epoxides with CO2 under Mild Conditions and Mechanistic Considerations

Milani, Jorge L. S.,Meireles, Alexandre M.,Bezerra, Werberson A.,Martins, Dayse. C. S.,Cangussu, Danielle,das Chagas, Rafael P.

, p. 4393 - 4402 (2019/08/01)

A series of 5,10,15,20-tetrakis(2,3-dichlorophenyl)porphyrinate complexes of manganese(III) [MnIII(T2,3DCPP)X] with six different axial ligands (X=NO3 ?, AcO?, IO3 ?, Br?, Cl?, HO?) were investigated as catalysts in the cycloaddition reactions of CO2 and styrene oxide (SO), under mild conditions, i. e., atmospheric pressure and 60 °C. [MnIIIT(2,3DCPP)IO3] showed the best catalytic performance, selectively producing the respective cyclic carbonate from diverse epoxides using tetrabutylammonium bromide as a nucleophile source. Mechanistic considerations were inferred from electronic spectra and spectrophotometric titrations, showing that there are a series of equilibriums involved in the formation of the catalytic active species. Stability constants for the proposed equilibrium models were determined using SQUAD software. A catalytic cycle has been proposed based on those observations.

Stereoselective Hydrolysis of Epoxides by reVrEH3, a Novel Vigna radiata Epoxide Hydrolase with High Enantioselectivity or High and Complementary Regioselectivity

Hu, Die,Tang, Cunduo,Li, Chuang,Kan, Tingting,Shi, Xiaoling,Feng, Lei,Wu, Minchen

, p. 9861 - 9870 (2017/11/22)

To provide more options for the stereoselective hydrolysis of epoxides, an epoxide hydrolase (VrEH3) gene from Vigna radiata was cloned and expressed in Escherichia coli. Recombinant VrEH3 displayed the maximum activity at pH 7.0 and 45 °C and high stability at pH 4.5-7.5 and 55 °C. Notably, reVrEH3 exhibited high and complementary regioselectivity toward styrene oxides 1a-3a and high enantioselectivity (E = 48.7) toward o-cresyl glycidyl ether 9a. To elucidate these interesting phenomena, the interactions of the three-dimensional structure between VrEH3 and enantiomers of 1a and 9a were analyzed by molecular docking simulation. Using E. coli/vreh3 whole cells, gram-scale preparations of (R)-1b and (R)-9a were performed by enantioconvergent hydrolysis of 100 mM rac-1a and kinetic resolution of 200 mM rac-9a in the buffer-free water system at 25 °C. These afforded (R)-1b with >99% eep and 78.7% overall yield after recrystallization and (R)-9a with >99% ees, 38.7% overall yield, and 12.7 g/L/h space-time yield.

Asymmetric hydrolysis of styrene oxide by PvEH2, a novel Phaseolus vulgaris epoxide hydrolase with extremely high enantioselectivity and regioselectivity

Li, Chuang,Hu, Die,Zong, Xun-Cheng,Deng, Chao,Feng, Lei,Wu, Min-Chen,Li, Jian-Fang

, p. 57 - 61 (2017/09/08)

A novel EH from Phaseolus vulgaris, PvEH2, was discovered based on the computer-aided analysis, and its encoding gene was cloned and expressed in E. coli Rossetta (DE3). The substrate spectrum of recombinant (re) PvEH2 was assayed, among which the enantiomeric ratio of rePvEH2 towards racemic styrene oxide (rac-1a) was > 200, while its regioselectivity coefficients, αS and βR, towards (S)- and (R)-1a were 99.1 and 69.8%, respectively. The asymmetric hydrolysis of 20 mM rac-1a by rePvEH2-expressing whole cells was performed at 25 °C, retaining (R)-1a with > 99.5% ees and 49.4% yield and producing (R)-phenyl-1,2-ethanediol (1b) with 96.2% eep and 49.7% yield in 40 min.

Asymmetric Hydrolytic and Aminolytic Kinetic Resolution of Racemic Epoxides using Recyclable Macrocyclic Chiral Cobalt(III) Salen Complexes

Tak, Rajkumar,Kumar, Manish,Menapara, Tusharkumar,Gupta, Naveen,Kureshy, Rukhsana I.,Khan, Noor-ul H.,Suresh

supporting information, p. 3990 - 4001 (2017/11/22)

New chiral macrocyclic cobalt(III) salen complexes were synthesized and used as catalyst for the asymmetric kinetic resolution (AKR) of terminal epoxides and glycidyl ethers with aromatic/aliphatic amines and water as nucleophiles. This is the first occasion where a Co(III) salen complex demonstrated its ability to catalyze AKR as well as hydrolytic kinetic resolution (HKR) reactions. Excellent enantiomeric excesses of the epoxides, the corresponding amino alcohols and diols (upto 99%) with quantitative yields were achieved by using the chiral Co(III) salen complexes in dichloromethane at room temperature. This protocol was further extended for the synthesis of two important drug molecules, i.e., (S)-propranolol and (R)-naftopidil. The catalytic system was also explored for the synthesis of chirally pure diols and chiral cyclic carbonates using carbon dioxide as a greener renewable C1 source. The catalyst was recycled for upto 5 catalytic cycles with retention of enantioselectivity. (Figure presented.).

A PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE

-

Paragraph 0158-0160, (2016/12/12)

Provided is a compound that exhibits an excellent melanogenesis-inhibiting effect (skin-lightening effect), exhibits an excellent antimicrobial effect, excels in terms of temporal stability and the like, and is suitable for use as an ingredient of a cosmetic. Said compound is a propyl-phenyl-ether derivative compound comprising a propyl group that has a substituent such as a hydroxyl group and is bound to the hydroxyl group of a phenol group that has a substituent such as a tert-butyl group. A melanogenesis inhibitor, skin-lightening agent, and antimicrobial agent containing the aforementioned compound as an active ingredient are also provided, as is a cosmetic characterized by containing said compound.

Three different types of chirality-driven crystallization within the series of uniformly substituted phenyl glycerol ethers

Bredikhin, Alexander A.,Bredikhina, Zemfira A.,Novikova, Victorina G.,Pashagin, Alexander V.,Zakharychev, Dmitry V.,Gubaidullin, Aidar T.

, p. 1092 - 1103 (2015/02/05)

Seven chiral arylglycerol ethers 2-R-C6H4-O-CH2CH(OH)CH2OH (R 5 H, Me, Et, Allyl, n-Pr, i-Pr, tert-Bu) were synthesized in racemic and scalemic form. The IR spectra, melting points, and enthalpies of fusion for racemic and scalemic samples of every species were measured, the entropies of enantiomers mixing in the liquid state and Gibbs free energies of a racemic compound formation were derived and binary phase diagrams were reconstructed for the whole family. Solid racemic compounds stabilities were ranked for the four substances. Spontaneous resolution was established for the registered chiral drug mephenesin and its ethyl analogue. Metastable anomalous conglomerate, forming crystals having three independent R and one independent S molecules in the unit cell, is formed during solution crystallization of tert-butyl derivative; metastable phase transforms slowly into traditional racemic conglomerate. Chirality 20:1092-1103, 2008.

Asymmetric hydrolytic kinetic resolution with recyclable polymeric Co(iii)-salen complexes: A practical strategy in the preparation of (S)-metoprolol, (S)-toliprolol and (S)-alprenolol: Computational rationale for enantioselectivity

Roy, Tamal,Barik, Sunirmal,Kumar, Manish,Kureshy, Rukhsana I.,Ganguly, Bishwajit,Khan, Noor-Ul H.,Abdi, Sayed H. R.,Bajaj, Hari C.

, p. 3899 - 3908 (2015/02/19)

A series of chiral polymeric Co(iii)-salen complexes based on a number of achiral and chiral linkers were synthesized and their catalytic performances were assessed in the asymmetric hydrolytic kinetic resolution of terminal epoxides. The effects of the linker were judiciously studied and it was found that in the case of the chiral BINOL-based polymeric salen complex 1, there was an enrichment in catalyst reactivity and enantioselectivity of the unreacted epoxide, particularly in the case of short as well as long chain aliphatic epoxides. Good isolated yields of the unreacted epoxide (up to 46% compared to 50% theoretical yield) along with high enantioselectivity (up to 99%) were obtained in most cases using catalyst 1. Further studies showed that catalyst 1 could retain its catalytic activity for six cycles under the present reaction conditions without any significant loss in activity or enantioselectivity. To show the practical applicability of the above synthesized catalyst we have synthesised some potent chiral β-blockers in moderate yield and high enantioselectivity using complex 1. The DFT (M06-L/6-31+G??//ONIOM(B3LYP/6-31G?:STO-3G)) calculations revealed that the chiral BINOL linker influences the enantioselectivity achieved with Co(iii)-salen complexes. Further, the transition state calculations show that the R-BINOL linker with the (S,S)-Co(iii)-salen complex is energetically preferred over the corresponding S-BINOL linker with the (S,S)-Co(iii)-salen complex for the HKR of 1,2-epoxyhexane. The role of non-covalent C-H?π interactions and steric effects has been discussed to control the HKR reaction of 1,2-epoxyhexane.

Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy

Hadimani, Mallinath B.,Purohit, Meena K.,Vanampally, Chandrashaker,Van Der Ploeg, Randy,Arballo, Victor,Morrow, Dwane,Frizzi, Katie E.,Calcutt, Nigel A.,Fernyhough, Paul,Kotra, Lakshmi P.

, p. 5071 - 5078 (2013/07/26)

In diabetic patients, an early index of peripheral neuropathy is the slowing of conduction velocity in large myelinated neurons and a lack of understanding of the basic pathogenic mechanisms hindered therapeutics development. Racemic (R/S)-guaifenesin (1) was identified as a potent enhancer of neurite outgrowth using an in vitro screen. Its R-enantiomer (R)-1 carried the most biological activity, whereas the S-enantiomer (S)-1 was inactive. Focused structural variations to (R/S)-1 was conducted to identify potentially essential groups for the neurite outgrowth activity. In vivo therapeutic studies indicated that both (R/S)-1 and (R)-1 partially prevented motor nerve conduction velocity slowing in a mouse model of type 1 diabetes. In vitro microsomal assays suggested that compounds (R)-1 and (S)-1 are not metabolized rapidly, and PAMPA assay indicated moderate permeability through the membrane. Findings revealed here could lead to the development of novel drugs for diabetic neuropathy.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 59-47-2